; (B) upon request by an applicant, conduct an informational site visit during the developmental phase to discuss requirements with the applicant with respect to facility design, site status, and validation; (C) not later than 30 days after conducting an informational site visit under subparagraph (B), provide advice and feedback to the applicant with respect to facility issues that may prevent approval of the supplemental application under subsection (a), including any issues with the facility transfer plans; and (D) participate in any pre-approval inspection required by the Secretary for an establishment or provide feedback to the Secretary with respect to a supplemental application described in subsection (a). (f) Additional informational visits Upon request by the applicant, the Secretary may conduct informational site visits in addition to an informational site visit conducted by the Facility Transfer Working Group under subsection (e). (g) Guidance (1) Issuance Not later than 1 year after the date of enactment of this section, the Secretary shall issue guidance with respect to this section. (2) Content The guidance issued under this paragraph shall include— (A) the process by which an applicant may seek expedited review and approval of a supplemental application under subsection (a); and (B) a description of the actions the Secretary may take to expedite the submission and review of such supplemental application. (h) Definitions In this section: (1) Satisfactory inspection history The term satisfactory inspection history means, with respect to a drug, a history consisting of one or more inspections in which the most recent manufacturing inspection was a satisfactory manufacturing inspection during which— (A) no objectionable conditions or practices were found